{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gruell H"],"funding":["Deutsches Zentrum für Infektionsforschung","Deutsche Forschungsgemeinschaft","Universität zu Köln","BMBF Bonn","Bundesinstitut für Arzneimittel und Medizinprodukte"],"pagination":["1231-1241.e6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9260412"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(9)"],"pubmed_abstract":["SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron sublineages BA.2.12.1 and BA.4/5 are rapidly becoming predominant in various countries. By determining polyclonal serum activity of 50 convalescent or vaccinated individuals against BA.1, BA.1.1, BA.2, BA.2.12.1, and BA.4/5, we reveal a further reduction in BA.4/5 susceptibility to vaccinee sera. Most notably, delineation of sensitivity to an extended 163-antibody panel demonstrates pronounced antigenic differences with distinct escape patterns among Omicron sublineages. Antigenic distance and/or higher resistance may therefore favor immune-escape-mediated BA.4/5 expansion after the first Omicron wave. Finally, while most clinical-stage monoclonal antibodies are inactive against Omicron sublineages, we identify promising antibodies with high pan-SARS-CoV-2 neutralizing potency. Our study provides a detailed understanding of Omicron-sublineage antibody escape that can inform on effective strategies against COVID-19."],"journal":["Cell host & microbe"],"pubmed_title":["SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns."],"pmcid":["PMC9260412"],"funding_grant_id":["CRC1310","V-2021.3/1503_68403/2021–2022","01KX2021"],"pubmed_authors":["Gruell H","Munn F","Tober-Lau P","Janicki H","Korenkov M","Klein F","Kreer C","Kurth F","Vanshylla K","Schommers P","Augustin M","Zehner M","Sander LE"],"additional_accession":[]},"is_claimable":false,"name":"SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.","description":"SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron sublineages BA.2.12.1 and BA.4/5 are rapidly becoming predominant in various countries. By determining polyclonal serum activity of 50 convalescent or vaccinated individuals against BA.1, BA.1.1, BA.2, BA.2.12.1, and BA.4/5, we reveal a further reduction in BA.4/5 susceptibility to vaccinee sera. Most notably, delineation of sensitivity to an extended 163-antibody panel demonstrates pronounced antigenic differences with distinct escape patterns among Omicron sublineages. Antigenic distance and/or higher resistance may therefore favor immune-escape-mediated BA.4/5 expansion after the first Omicron wave. Finally, while most clinical-stage monoclonal antibodies are inactive against Omicron sublineages, we identify promising antibodies with high pan-SARS-CoV-2 neutralizing potency. Our study provides a detailed understanding of Omicron-sublineage antibody escape that can inform on effective strategies against COVID-19.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-05-28T00:37:37.963Z","creation":"2025-04-22T16:36:10.221Z"},"accession":"S-EPMC9260412","cross_references":{"pubmed":["35921836"],"doi":["10.1016/j.chom.2022.07.002"]}}